1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Ischemic Cardiomyopathy – Pipeline Review, H1 2013

Ischemic Cardiomyopathy – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 37 pages

Ischemic Cardiomyopathy – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Ischemic Cardiomyopathy - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Cardiomyopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Cardiomyopathy. Ischemic Cardiomyopathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ischemic Cardiomyopathy.
- A review of the Ischemic Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ischemic Cardiomyopathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ischemic Cardiomyopathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ischemic Cardiomyopathy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Ischemic Cardiomyopathy - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Ischemic Cardiomyopathy Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Ischemic Cardiomyopathy 7
Ischemic Cardiomyopathy Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Ischemic Cardiomyopathy Therapeutics - Products under Development by Companies 14
Companies Involved in Ischemic Cardiomyopathy Therapeutics Development 15
Bioheart, Inc. 15
Cytokinetics, Inc 16
LG Life Sciences, Ltd 17
Ischemic Cardiomyopathy - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
omecamtiv mecarbil - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Lipicell - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
NecroX-7 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
MonoCell - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Ischemic Cardiomyopathy Therapeutics - Drug Profile Updates 29
Ischemic Cardiomyopathy - Product Development Milestones 33
Featured News and Press Releases 33
Feb 28, 2012: Bioheart Announces University Of Miami As Clinical Site For ANGEL Trial Of LipiCell 33
Dec 06, 2011: Bioheart Files With FDA To Begin ANGEL Trial 33
Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy 33
Apr 05, 2011: Cardio3 BioSciences Announces Results Of C-Cure Phase II Clinical Trial At 60th Annual American College Of Cardiology Meeting 34
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37



List of Tables

Number of Products Under Development for Ischemic Cardiomyopathy, H1 2013 7
Products under Development for Ischemic Cardiomyopathy - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Bioheart, Inc., H1 2013 15
Cytokinetics, Inc, H1 2013 16
LG Life Sciences, Ltd, H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 22
Ischemic Cardiomyopathy Therapeutics - Drug Profile Updates 29



List of Figures

Number of Products under Development for Ischemic Cardiomyopathy, H1 2013 7
Products under Development for Ischemic Cardiomyopathy - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 18
Assessment by Route of Administration, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Molecule Type, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glutamyl Aminopeptidase ...

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) ...

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘NADPH ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.